NCT03608566 (RSAR) is a clinical trial in Severe Asthma, sponsored by Interregional Public Organization, Russian Respiratory Society.

Who is sponsoring NCT03608566?

NCT03608566 is sponsored by Interregional Public Organization, Russian Respiratory Society.

What condition does NCT03608566 study?

NCT03608566 studies Severe Asthma.

Is NCT03608566 still recruiting?

NCT03608566 is currently status unknown. Last updated 10 August 2018.

Last reviewed 2018-08-10 · How we verify

NCT03608566: RSAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Russian Severe Asthma Registry

Status unknown Last updated 10 August 2018

What this trial tests

trial in Severe Asthma in 7,000 participants. Status unknown.

Timeline

30 March 2018

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Interregional Public Organization, Russian Respiratory Society
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	7,000
Start date	30 March 2018
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Russia

Conditions studied

Severe Asthma — all drugs for Severe Asthma →

Sponsor

Interregional Public Organization, Russian Respiratory Society

Who can join

12 and older, any sex, with Severe Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Russian Severe Asthma Registry is a Russian initiative to collect anonymous long-term evidence for patients with severe asthma in Russia

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Digital Technology Tools to Examine Patient Adherence to a Prescription-Only Omega-3 Polyunsaturated Fatty Acid Therapy To Mitigate Cardiovascular Risk: Protocol for a Prospective Observational Study and Preliminary Demographic Analysis.
Arutyunov GP, Arutyunov AG, Ageev FT, Fofanova TV. · · 2021 · cited 2× · PMID 34459746 · DOI 10.2196/29061

Verify or expand the search:

Other recruiting trials for Severe Asthma

Currently open trials in the same condition.

NCT07363642 — Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab · Phase 3 · recruiting
NCT07328035 — Remission in Adults With Severe Asthma in Thailand · recruiting
NCT07530770 — Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis · recruiting
NCT06903780 — Experience of Biologic Treatments for Severe Asthma: a Survey · recruiting
NCT06681545 — Exploring the Lived Experience of Young Adults With Severe Asthma · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03608566 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Interregional Public Organization, Russian Respiratory Society
Last refreshed: 10 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03608566.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing